Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERCP-RFA with Envafolimab and Surufatinib for Unresectable Biliary Tract Carcinoma
NCT06656559Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Modality
- Fragment-Derived Small Molecules, Orthosteric Ligands, Nanobodies (VHH)
01
Overview
Phase 2, open-label, single-arm trial of envafolimab and surufatinib in biliary tract carcinoma (BTC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Overall Survival at 12 months. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
envafolimabsurufatinib
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT06656559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06656559.